Download pdf
PLGA Nanoparticle Formation Based on Formulae Incorporating Different Proportions of DOTAP
- 1 Beijing Royal School, Wangfu Street No.11, Beijing, China
* Author to whom correspondence should be addressed.
Abstract
The polymer poly(lactic-co-glycolic acid) (PLGA) emulsifies in aqueous conditions to form nanoparticles. Such vesicles are frequently involved in drug delivery, of vaccines for instance, due to several advantages, such as high structural stability, low cytotoxicity and biodegradability. Incorporating lipids onto surfaces of such nanoparticles enhances their effectiveness in cellular internalization. However, the effects on structural integrity in terms of the entire polymer-lipid particle of incorporating lipids onto polymeric nanoparticles is rather less fathomed. In this article we synthesized PLGA vesicles via ultrasonication of suspensions of PLGA as the hydrophobic phase, deionized (DI) water as the inner aqueous phase, and 30% ethanol as the outer aqueous phase. The hydrophobic phase was pre-added 1,2-dioleoyl-3-trimethylammonium propane (DOTAP) in different ratios. The resulting vesicles were presented with scan electron micrographs (SEMs), and were measured their sizes and zeta-potentials. Average zeta potential increased as proportion of lipid to polymer increased, while in all samples there were polydispersion, suggesting the possibility of nanoparticles dissembled. We suggest that the ratio leading to the highest average zeta potential is within the interval between 1:6 and 1:4, or greater than 1:4.
Keywords
Nanoparticle, Stability, Zeta potential, Dispersion
[1]. Agrawal, Akhil, Sandeep Rellegadla, and Shikha Jain. 2019. “Biomedical Applications of PLGA Particles.” Elsevier EBooks, January, 87–129. https://doi.org/10.1016/b978-0-12-816913-1.00004-0.
[2]. Hadinoto, Kunn, Ajitha Sundaresan, and Wean Sin Cheow. 2013. “Lipid–Polymer Hybrid Nanoparticles as a New Generation Therapeutic Delivery Platform: A Review.” European Journal of Pharmaceutics and Biopharmaceutics 85 (3): 427–43. https://doi.org/10.1016/j.ejpb.2013.07.002.
[3]. Wu, Libo, Jian Zhang, and Wiwik Watanabe. 2011. “Physical and Chemical Stability of Drug Nanoparticles.” Advanced Drug Delivery Reviews 63 (6): 456–69. https://doi.org/10.1016/j.addr.2011.02.001.
[4]. Yu, Min, Ke Wang, Han Zhang, Qian Liu, Jin Wang, Li Cao, Wenjing Li, Kai Wang, and Zhangyong Hong. 2018. “DOTAP-Incorporated PEG-PLGA Nanoparticles for Efficient in Vitro and in Vivo Gene Delivery.” Journal of Biomedical Nanotechnology 14 (2): 281–93. https://doi.org/10.1166/jbn.2018.2470.
[5]. Zhong, Qiu, Dakshina Chinta, Sarala Pamujula, Haifan Wang, Xin Yao, Tarun K Mandal, and Ronald B Luftig. 2010. “Optimization of DNA Delivery by Three Classes of Hybrid Nanoparticle/DNA Complexes.” Journal of Nanobiotechnology 8 (1): 6–6. https://doi.org/10.1186/1477-3155-8-6.
[6]. Cheow, Wean Sin, and Kunn Hadinoto. 2011. “Factors Affecting Drug Encapsulation and Stability of Lipid–Polymer Hybrid Nanoparticles.” Colloids and Surfaces B: Biointerfaces 85 (2): 214–20. https://doi.org/10.1016/j.colsurfb.2011.02.033.
[7]. Zhao, Peiqi, Hanjie Wang, Man Yu, Zhenyu Liao, Xianhuo Wang, Fei Zhang, Wei Ji, et al. 2012. “Paclitaxel Loaded Folic Acid Targeted Nanoparticles of Mixed Lipid-Shell and Polymer-Core: In Vitro and in Vivo Evaluation.” European Journal of Pharmaceutics and Biopharmaceutics 81 (2): 248–56. https://doi.org/10.1016/j.ejpb.2012.03.004.
[8]. Yang, Xian-Zhu, Shuang Dou, Yu-Cai Wang, Hong-Yan Long, Meng-Hua Xiong, Cheng-Qiong Mao, Yan-Dan Yao, and Jun Wang. 2012. “Single-Step Assembly of Cationic Lipid–Polymer Hybrid Nanoparticles for Systemic Delivery of SiRNA.” ACS Nano 6 (6): 4955–65. https://doi.org/10.1021/nn300500u.
Cite this article
Liu,P. (2025). PLGA Nanoparticle Formation Based on Formulae Incorporating Different Proportions of DOTAP. Theoretical and Natural Science,96,35-39.
Data availability
The datasets used and/or analyzed during the current study will be available from the authors upon reasonable request.
Disclaimer/Publisher's Note
The statements, opinions and data contained in all publications are solely those of the individual author(s) and contributor(s) and not of EWA Publishing and/or the editor(s). EWA Publishing and/or the editor(s) disclaim responsibility for any injury to people or property resulting from any ideas, methods, instructions or products referred to in the content.
About volume
Volume title: Proceedings of the 5th International Conference on Biological Engineering and Medical Science
© 2024 by the author(s). Licensee EWA Publishing, Oxford, UK. This article is an open access article distributed under the terms and
conditions of the Creative Commons Attribution (CC BY) license. Authors who
publish this series agree to the following terms:
1. Authors retain copyright and grant the series right of first publication with the work simultaneously licensed under a Creative Commons
Attribution License that allows others to share the work with an acknowledgment of the work's authorship and initial publication in this
series.
2. Authors are able to enter into separate, additional contractual arrangements for the non-exclusive distribution of the series's published
version of the work (e.g., post it to an institutional repository or publish it in a book), with an acknowledgment of its initial
publication in this series.
3. Authors are permitted and encouraged to post their work online (e.g., in institutional repositories or on their website) prior to and
during the submission process, as it can lead to productive exchanges, as well as earlier and greater citation of published work (See
Open access policy for details).